Synergistic action of amphotericin B and rifampin against Rhizopus species

John Christenson, I. Shalit, D. F. Welch, A. Guruswamy, M. I. Marks

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

A 16-year-old diabetic patient developed Rhizopus pneumonia and was initially treated with amphotericin B for 7 days. Because of clinical deterioration of the patient, rifampin was added empirically. The patient improved clinically, and lung tissue removed surgically 8 weeks later showed no fungal elements by histopathological studies or by culture. An in vitro study of amphotericin B alone and in combination with rifampin against the isolate from the patient and 11 additional isolates of Rhizopus spp. was designed. The activity of amphotericin B in the presence of rifampin (10 or 5 μg/ml) increased fourfold against 9 of 10 clinical and 1 of 2 environmental isolates. Amphotericin B activity in the presence of 2 μg of rifampin per ml increased fourfold against 6 of 10 clinical isolates and increased twofold against an additional 3 clinical isolates. Amphotericin B in the presence of 1 μg of rifampin per ml inhibited 9 of 10 isolates at a concentration of one-half the MIC of amphotericin B alone. These findings were confirmed by dose-reponse curves calculated from fungal dry weight determinations of Rhizopus spp. incubated in serial dilutions of amphotericin B combined with rifampin. These observations demonstrate in vitro, and possibly in vivo, synergy between amphotericin B and rifampin against Rhizopus spp.

Original languageEnglish (US)
Pages (from-to)1775-1778
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume31
Issue number11
StatePublished - 1987
Externally publishedYes

Fingerprint

Rhizopus
Amphotericin B
Rifampin
Pneumonia
Weights and Measures
Lung

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Christenson, J., Shalit, I., Welch, D. F., Guruswamy, A., & Marks, M. I. (1987). Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrobial Agents and Chemotherapy, 31(11), 1775-1778.

Synergistic action of amphotericin B and rifampin against Rhizopus species. / Christenson, John; Shalit, I.; Welch, D. F.; Guruswamy, A.; Marks, M. I.

In: Antimicrobial Agents and Chemotherapy, Vol. 31, No. 11, 1987, p. 1775-1778.

Research output: Contribution to journalArticle

Christenson, J, Shalit, I, Welch, DF, Guruswamy, A & Marks, MI 1987, 'Synergistic action of amphotericin B and rifampin against Rhizopus species', Antimicrobial Agents and Chemotherapy, vol. 31, no. 11, pp. 1775-1778.
Christenson, John ; Shalit, I. ; Welch, D. F. ; Guruswamy, A. ; Marks, M. I. / Synergistic action of amphotericin B and rifampin against Rhizopus species. In: Antimicrobial Agents and Chemotherapy. 1987 ; Vol. 31, No. 11. pp. 1775-1778.
@article{0098517878ab4d85a020be1b73da144c,
title = "Synergistic action of amphotericin B and rifampin against Rhizopus species",
abstract = "A 16-year-old diabetic patient developed Rhizopus pneumonia and was initially treated with amphotericin B for 7 days. Because of clinical deterioration of the patient, rifampin was added empirically. The patient improved clinically, and lung tissue removed surgically 8 weeks later showed no fungal elements by histopathological studies or by culture. An in vitro study of amphotericin B alone and in combination with rifampin against the isolate from the patient and 11 additional isolates of Rhizopus spp. was designed. The activity of amphotericin B in the presence of rifampin (10 or 5 μg/ml) increased fourfold against 9 of 10 clinical and 1 of 2 environmental isolates. Amphotericin B activity in the presence of 2 μg of rifampin per ml increased fourfold against 6 of 10 clinical isolates and increased twofold against an additional 3 clinical isolates. Amphotericin B in the presence of 1 μg of rifampin per ml inhibited 9 of 10 isolates at a concentration of one-half the MIC of amphotericin B alone. These findings were confirmed by dose-reponse curves calculated from fungal dry weight determinations of Rhizopus spp. incubated in serial dilutions of amphotericin B combined with rifampin. These observations demonstrate in vitro, and possibly in vivo, synergy between amphotericin B and rifampin against Rhizopus spp.",
author = "John Christenson and I. Shalit and Welch, {D. F.} and A. Guruswamy and Marks, {M. I.}",
year = "1987",
language = "English (US)",
volume = "31",
pages = "1775--1778",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Synergistic action of amphotericin B and rifampin against Rhizopus species

AU - Christenson, John

AU - Shalit, I.

AU - Welch, D. F.

AU - Guruswamy, A.

AU - Marks, M. I.

PY - 1987

Y1 - 1987

N2 - A 16-year-old diabetic patient developed Rhizopus pneumonia and was initially treated with amphotericin B for 7 days. Because of clinical deterioration of the patient, rifampin was added empirically. The patient improved clinically, and lung tissue removed surgically 8 weeks later showed no fungal elements by histopathological studies or by culture. An in vitro study of amphotericin B alone and in combination with rifampin against the isolate from the patient and 11 additional isolates of Rhizopus spp. was designed. The activity of amphotericin B in the presence of rifampin (10 or 5 μg/ml) increased fourfold against 9 of 10 clinical and 1 of 2 environmental isolates. Amphotericin B activity in the presence of 2 μg of rifampin per ml increased fourfold against 6 of 10 clinical isolates and increased twofold against an additional 3 clinical isolates. Amphotericin B in the presence of 1 μg of rifampin per ml inhibited 9 of 10 isolates at a concentration of one-half the MIC of amphotericin B alone. These findings were confirmed by dose-reponse curves calculated from fungal dry weight determinations of Rhizopus spp. incubated in serial dilutions of amphotericin B combined with rifampin. These observations demonstrate in vitro, and possibly in vivo, synergy between amphotericin B and rifampin against Rhizopus spp.

AB - A 16-year-old diabetic patient developed Rhizopus pneumonia and was initially treated with amphotericin B for 7 days. Because of clinical deterioration of the patient, rifampin was added empirically. The patient improved clinically, and lung tissue removed surgically 8 weeks later showed no fungal elements by histopathological studies or by culture. An in vitro study of amphotericin B alone and in combination with rifampin against the isolate from the patient and 11 additional isolates of Rhizopus spp. was designed. The activity of amphotericin B in the presence of rifampin (10 or 5 μg/ml) increased fourfold against 9 of 10 clinical and 1 of 2 environmental isolates. Amphotericin B activity in the presence of 2 μg of rifampin per ml increased fourfold against 6 of 10 clinical isolates and increased twofold against an additional 3 clinical isolates. Amphotericin B in the presence of 1 μg of rifampin per ml inhibited 9 of 10 isolates at a concentration of one-half the MIC of amphotericin B alone. These findings were confirmed by dose-reponse curves calculated from fungal dry weight determinations of Rhizopus spp. incubated in serial dilutions of amphotericin B combined with rifampin. These observations demonstrate in vitro, and possibly in vivo, synergy between amphotericin B and rifampin against Rhizopus spp.

UR - http://www.scopus.com/inward/record.url?scp=0023640975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023640975&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1775

EP - 1778

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -